Results 221 to 230 of about 28,869 (265)

Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis

Journal of Viral Hepatitis
Clinical studies of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) treatment in patients with HBV‐related decompensated cirrhosis (HBV‐DC) are limited.
X. Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan   +7 more
semanticscholar   +1 more source

Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment

Expert Opinion on Drug Metabolism & Toxicology
Introduction The combination of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) represents a valid option of antiretroviral therapy (ART) as first line regimen both in ART-naïve and -experienced people with HIV (PWH).
E. Bruzzesi, C. Muccini, A. Castagna
semanticscholar   +1 more source

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort

JHEP Reports
Background & Aims Tenofovir alafenamide (TAF) lacks extensive research regarding its impact on hepatocellular carcinoma (HCC). This study evaluated and compared the effects of TAF, tenofovir disoproxil fumarate (TDF), and entecavir (ETV) on HCC incidence
H. Yoo, Jae-Young Kim, Jeong-Ju Yoo, H. Lee, Sang Gyune Kim, Young Seok Kim   +5 more
semanticscholar   +1 more source

Fanconi Syndrome and Tenofovir Alafenamide

Annals of Internal Medicine, 2019
Hortensia, Álvarez, Josep M, Llibre
openaire   +4 more sources

Effect of 2 Forms of Tenofovir on Duodenal Enterocytes—A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma Lipids

Clinical Infectious Diseases
Background Tenofovir disoproxil fumarate (TDF), compared to tenofovir alafenamide (TAF), leads to lower body weight and plasma lipids by an unknown mechanism.
Kai Juhani Kauppinen, I. Aho, Nelli Sjöblom, O. Tynninen, Anu Suomalainen, Ursula Schwab, Fang Zhao, P. Arkkila, Jussi Sutinen   +8 more
semanticscholar   +1 more source

[Tenofovir alafenamide fumarate - a new generation of tenofovir].

Klinicka mikrobiologie a infekcni lekarstvi, 2018
Antiretroviral therapy as a life-long treatment has to meet the criteria of maximum efficiency while maintaining the highest possible level of safety and tolerance. Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug with an excellent effect of virological suppression.
Svatava, Snopková, Kateřina, Havlíčková, Petr, Husa   +2 more
openaire   +1 more source

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).

Clinical Infectious Diseases
BACKGROUND QUANTI-TAF aimed to establish tenofovir-diphosphate/emtricitabine-triphosphate (TFV-DP/FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with HIV (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)-based ...
R. Coyle, Mary Morrow, Sarah C Mann, Vincent Mainella, Samuel L. Ellis, S. Schwab, Corwin Coppinger, N. Barker, L. Ellison, Jia-Hua Zheng, Subhi Al Zuabi, Pamela E Alpert, T. C. Carnes, D. E. Buffkin, Peter R. Chai, L. Bushman, J. Kiser, Samantha MaWhinney, Kristina M. Brooks, P. Anderson, J. Castillo-Mancilla   +20 more
semanticscholar   +1 more source

Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.

The Lancet HIV
BACKGROUND Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to
Carina A Rodriguez, E. Natukunda, Renate Strehlau, E. L. Venter, S. Rungmaitree, Coleen K. Cunningham, Umesh G. Lalloo, P. Kosalaraksa, Elizabeth Hellström, A. Liberty, E. McGrath, M. Kaur, R. Leisegang, J. Hindman, V. Vieira, Kathryn Kersey, Mark F. Cotton, N. Rakhmanina, Aditya H Gaur   +18 more
semanticscholar   +1 more source

Tenofovir alafenamide

Reactions Weekly, 2023
openaire   +1 more source

Tenofovir alafenamide

Reactions Weekly, 2018
openaire   +2 more sources